Cavaleri v. Amgen Inc.

CourtDistrict Court, E.D. New York
DecidedMarch 8, 2021
Docket1:20-cv-01762
StatusUnknown

This text of Cavaleri v. Amgen Inc. (Cavaleri v. Amgen Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cavaleri v. Amgen Inc., (E.D.N.Y. 2021).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK -------------------------------------------------------x GIANLUCA CAVALERI,

Plaintiff, MEMORANDUM & ORDER - against - 20-CV-1762 (PKC) (RML)

AMGEN INC., and IMMUNEX CORPORATION,

Defendants. -------------------------------------------------------x PAMELA K. CHEN, United States District Judge: Plaintiff Gianluca Cavaleri brought this products liability action against Defendants Amgen Inc. (“Amgen”) and Immunex Corporation (“Immunex”) in the Supreme Court of New York, Queens County. On April 10, 2020, Defendants removed the action to this Court and subsequently moved to dismiss the Complaint under Federal Rule of Civil Procedure 12(b)(6), for failure to state a claim for relief. Because the Court lacks subject-matter jurisdiction, it must sua sponte remand this action to the state court. BACKGROUND In 2011, Plaintiff began taking Defendants’ drug Enbrel to treat psoriatic arthritis. (Complaint, Dkt. 1-2, ¶ 8.) Plaintiff alleges that, as a result of taking Enbrel, he was diagnosed in 2017 with chronic inflammatory demyelinating polyneuropathy (“CIDP”) and has suffered other “serious chronic debilitating injuries and illness,” including “numbness and muscle weakness throughout his body . . . , pain in legs when walking, poor balance, loss of strength in arms, paralysis of left hand, optic neuritis, erectile disfunction [sic], speech impairment, [and] depression.” (Id. ¶¶ 10–13.) Plaintiff’s Complaint, filed in state court, asserts damages that “exceed[] the jurisdictional limits of all lower courts which would otherwise have jurisdiction,” but does not specify any amount. (See id. ¶¶ 15, 21, 27.) In removing this case, Defendants invoked this Court’s diversity jurisdiction under 28 U.S.C. § 1332 as the basis for federal subject-matter jurisdiction. (Notice of Removal (“Notice”), Dkt. 1, ¶ 4.) Defendants alleged that complete diversity exists because Plaintiff is a citizen of New

York, Defendant Amgen is a Delaware corporation with its principal place of business in California, and Defendant Immunex is a Delaware corporation with its principal place of business in California. (Id. ¶¶ 5–8.) As for the amount in controversy, Defendants admitted that the Complaint “does not specify the amount of money damages sought,” but Defendants argued that, given the injuries alleged, “the face of the Complaint demonstrates that the amount in controversy exceeds $75,000, exclusive of interest and costs.” (Id. ¶ 10.) Upon removal, Defendants moved to dismiss the Complaint. (See Dkts. 7, 13.) Plaintiff has responded to Defendants’ motion, but otherwise has not contested the Court’s jurisdiction or moved to remand. (See Dkts. 10, 14.) DISCUSSION It is axiomatic that “failure of subject matter jurisdiction is not waivable and may be raised

at any time by a party or by the court sua sponte.” Lyndonville Sav. Bank & Tr. Co. v. Lussier, 211 F.3d 697, 700 (2d Cir. 2000); see also Shakour v. Fed. Republic of Ger., 199 F. Supp. 2d 8, 12 (E.D.N.Y. 2002) (“District courts must police subject matter jurisdiction on their own initiative.” (citations omitted)). Indeed, the removal provisions explicitly provide: “If at any time before final judgment it appears that the district court lacks subject matter jurisdiction, the case shall be remanded.” 28 U.S.C. § 1447(c). The Second Circuit has construed this statutory provision as authorizing a district court to remand a case sua sponte at any time upon finding that it lacks subject-matter jurisdiction. See Mitskovski v. Buffalo & Fort Erie Pub. Bridge Auth., 435 F.3d 127, 133 (2d Cir. 2006) (citing, inter alia, Bender v. Williamsport Area Sch. Dist., 475 U.S. 534, 541 (1986)). In any case removed from state court on the basis of federal diversity jurisdiction, the removing party bears the burden of establishing that the amount in controversy exceeds the $75,000 jurisdictional threshold mandated by 28 U.S.C. § 1332(a). See Lupo v. Hum. Affs. Int’l,

Inc., 28 F.3d 269, 273 (2d Cir. 1994) (citing McNutt v. Gen. Motors Acceptance Corp., 298 U.S. 178, 189 (1936)). Where “the jurisdictional amount is not clearly alleged in the plaintiff’s complaint, and the defendant’s notice of removal fails to allege facts adequate to establish that the amount in controversy exceeds the jurisdictional amount, federal courts lack diversity jurisdiction as a basis for removing the plaintiff’s action from state court.” Id. at 273–74 (citation omitted). “[I]n light of the congressional intent to restrict federal court jurisdiction, as well as the importance of preserving the independence of state governments, federal courts construe the removal statute narrowly, resolving any doubts against removability.” Purdue Pharma L.P. v. Kentucky, 704 F.3d 208, 213 (2d Cir. 2013) (quoting Lupo, 28 F.3d at 274). Indeed, “a case filed in state court does

not become removable [on the basis of diversity jurisdiction] until the plaintiff serves the defendant with a paper that explicitly specifies the amount of monetary damages sought.” Daversa v. Cowan Equip. Leasing LLC, No. 20-CV-163 (WFK) (RLM), 2020 WL 967436, at *2 (E.D.N.Y. Feb. 28, 2020) (internal quotation marks omitted) (citing Moltner v. Starbucks Coffee Co., 624 F.3d 34, 38 (2d Cir. 2010) (per curiam)); accord Noguera v. Bedard, No. 11-CV-4893 (RRM) (ALC), 2011 WL 5117598, at *1 (E.D.N.Y. Oct. 26, 2011) (quoting Moltner). Here, Defendants fail to meet their burden of showing that the jurisdictional amount in controversy required for diversity jurisdiction is satisfied. As Defendants admit, the Complaint “does not specify the amount of money damages sought.”1 (Notice, Dkt. 1, ¶ 10). Nor have Defendants requested and been served with any document that specifies the alleged damages.2 Defendants instead rely on the injuries alleged in the Complaint to argue that “the face of the Complaint demonstrates that the amount in controversy exceeds $75,000.” (Id.) In particular, Defendants rely on Plaintiff’s allegation that he has suffered “chronic debilitating injuries and

illness,” including CIDP, numbness and muscle weakness throughout the body, pain in the legs when walking, poor balance, loss of strength in the arms, paralysis of the left hand, optic neuritis, erectile dysfunction, speech impairment, and depression. (Id. (quoting Complaint, Dkt. 1-2, ¶¶ 12– 13).) But these allegations do not permit the Court to draw a reasonable inference that the specific amount in controversy exceeds $75,000. See, e.g., Brown v. NutriBullet, LLC, No. 19-CV-5421 (PKC) (ST), 2019 WL 5287960, at *2 (E.D.N.Y. Oct.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Cavaleri v. Amgen Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/cavaleri-v-amgen-inc-nyed-2021.